Abstract
The physiological VDR ligand, 1α,25-dihydroxyvitamin D3, acts upon a wide variety of tissues and cells, both related to and unrelated to calcium and phosphate homeostasis. The noncalcemic actions of natural and synthetic VDR ligands are exemplified by their potent anti-proliferative, prodifferentiative and immunomodulatory activities. As a result, a VDR ligand is an approved drug for the topical treatment of psoriasis. A plethora of actions of 1α,25-dihydroxyvitamin D3 in various systems have suggested wide clinical applications of VDR ligands in such diverse disease states as inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, photoaging and skin rejuvenation), osteoporosis, cancers (breast, prostate, colon, leukemia and myelodysplastic syndrome) and autoimmune diseases (multiple sclerosis, type I diabetes and systemic lupus erythematosus). VDR ligands have shown therapeutic potential in limited human clinical trials as well as in animal models of these diseases. Some of the VDR ligands have shown not only potent preventive but also therapeutic anabolic activities in animal models of osteoporosis. However, the use of VDR in above mentioned indications as well as in oral therapy for psoriasis and even topical therapy for severe psoriasis is hampered by its associated toxicity, namely hypercalcemia. New VDR ligands have been synthesized which exhibit greater specificity by retaining desirable properties, but with reduced calcemic potential. The discovery of novel vitamin D3 analogs along with an increased understanding of the biological functions and mechanisms of action of VDR are likely to result in improved treatments for responsive indications.
Current Medicinal Chemistry
Title: Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Volume: 8 Issue: 13
Author(s): Sunil Nagpal, Jianfen Lu and Marcus F. Boehm
Affiliation:
Abstract: The physiological VDR ligand, 1α,25-dihydroxyvitamin D3, acts upon a wide variety of tissues and cells, both related to and unrelated to calcium and phosphate homeostasis. The noncalcemic actions of natural and synthetic VDR ligands are exemplified by their potent anti-proliferative, prodifferentiative and immunomodulatory activities. As a result, a VDR ligand is an approved drug for the topical treatment of psoriasis. A plethora of actions of 1α,25-dihydroxyvitamin D3 in various systems have suggested wide clinical applications of VDR ligands in such diverse disease states as inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, photoaging and skin rejuvenation), osteoporosis, cancers (breast, prostate, colon, leukemia and myelodysplastic syndrome) and autoimmune diseases (multiple sclerosis, type I diabetes and systemic lupus erythematosus). VDR ligands have shown therapeutic potential in limited human clinical trials as well as in animal models of these diseases. Some of the VDR ligands have shown not only potent preventive but also therapeutic anabolic activities in animal models of osteoporosis. However, the use of VDR in above mentioned indications as well as in oral therapy for psoriasis and even topical therapy for severe psoriasis is hampered by its associated toxicity, namely hypercalcemia. New VDR ligands have been synthesized which exhibit greater specificity by retaining desirable properties, but with reduced calcemic potential. The discovery of novel vitamin D3 analogs along with an increased understanding of the biological functions and mechanisms of action of VDR are likely to result in improved treatments for responsive indications.
Export Options
About this article
Cite this article as:
Nagpal Sunil, Lu Jianfen and Boehm F. Marcus, Vitamin D Analogs: Mechanism of Action and Therapeutic Applications, Current Medicinal Chemistry 2001; 8 (13) . https://dx.doi.org/10.2174/0929867013371950
DOI https://dx.doi.org/10.2174/0929867013371950 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Macrophages in Inflammation
Current Drug Targets - Inflammation & Allergy Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry IL-22 Produced by T helper Cell 22 as a New player in the Pathogenesis of Immune Thrombocytopenia
Endocrine, Metabolic & Immune Disorders - Drug Targets The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Resources and Tools for Investigating Biomolecular Networks in Mammals
Current Pharmaceutical Design From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Capillary Electrophoresis Determination of Tiopronin in Human Urine After Derivatization with 2-chloro-1-methylquinolinium Tetrafluoroborate
Current Analytical Chemistry IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets Update on Targets of Biologic Therapies for Rheumatoid Arthritis
Current Rheumatology Reviews Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) “Bedside-to-Bench” Behavioral Outcomes in Animal Models of Pain: Beyond the Evaluation of Reflexes
Current Neuropharmacology Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Enhanced Activity of pSTAT-3 Ser-727 in Functional Endothelial Cells Under Calcifying Conditions
Current Chemical Biology Review of Patents for Microneedle Application Devices Allowing Fluid Injections Through the Skin
Recent Patents on Drug Delivery & Formulation